COMP <GO>
ALNY vs ABBV // FREE CASH FLOW YIELD
Alnylam Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: ALNY 6
— ABBV 9
▲ FREE CASH FLOW YIELD LEADER: ABBV
LAST: $165.00 (-5.17%) • MKT CAP: $23.28B
fcf-yield
2.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
fcf-yield
3.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALNY VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ALNY | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.80% | 70.20% | +11.60 | ALNY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 21.30% | 29.00% | -7.70 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 42.4x | 33.3x | +9.10 | ABBV | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 2.00% | 3.47% | -1.47 | ABBV | /fcf-yield <GO> |
| Operating Margin | 13.50% | 24.60% | -11.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 6.90% | +1.50 | ALNY | /net-margins <GO> |
| Revenue Growth (YoY) | 65.20% | 8.60% | +56.60 | ALNY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.16 | 5.33 | -2.17 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ALNY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | ALNY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 22.1 | 72.8 | -50.73 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 62.3x | 113.1x | -50.80 | ALNY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.28B | $513.86B | -$490.58B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ALNY REV | ABBV REV | ALNY GROSS % | ABBV GROSS % | ALNY FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.71B | $61.16B | 81.8% | 70.2% | $465.4M | $17.82B |
| FY 2024 | $2.25B | $56.33B | 86.4% | 70.0% | -$42.6M | $17.83B |
| FY 2023 | $1.83B | $54.32B | 44.0% | 44.0% | $21.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALNY // BETA 1.00
ABBV // BETA 1.15